openPR Logo
Press release

Neuroendocrine Carcinoma Market Analysis & Key Trends 2020

01-18-2018 10:55 AM CET | Health & Medicine

Press release from: Transparency Market Research

Neuroendocrine Carcinoma Market Analysis & Key Trends 2020

A neuroendocrine tumor is a kind of tumor that begins in the hormone producing cells of the neuroendocrine system that is made up of the endocrine system and nervous system. Hormones producing neuroendocrine cells have a structure similar to neurons and produce hormones like endocrine cells. These cells are found throughout the body in organs such as intestines, kidneys, lungs and stomach and perform functions such as controlling the speed of food through gastrointestinal tract and air and blood flow through the lungs.

Report Overview @ https://www.transparencymarketresearch.com/neuroendocrine-carcinoma-market.html

Neuroendocrine tumor is a rare malignant disorder that accounts for nearly one percent of all malignant disorders. Neuroendocrine carcinomas account for nearly 60% of all neuroendocrine tumor cases and are characterized as their origin in different locations throughout the body including lungs, gastrointestinal tract and brain. Some common symptoms associated with neuroendocrine carcinoma are hyperglycemia, hypoglycemia, weight loss, loss of appetite, headache, anxiety, gastric ulcer, unusual bleeding, jaundice, diarrhea, fever and persistent in specific area.

The treatment options for neuroendocrine carcinoma include surgery, radiation therapy and chemotherapy. Chemotherapy involves the use of drugs to kill cancerous cells by inhibiting the cells ability to grow and divide. Streptozocin (Zanosar) and 5-fluorouracil (Adrucil, 5-FU) are some drugs that are used to treat neuroendocrine carcinomas. Continuous efforts by major pharmaceuticals in order to develop targeted therapy have been contributing in the growth of neuroendocrine carcinomas market. Everolimus (Afinitor) and sunitinib (Sutent) are two major targeted drugs that are being used for treating neuroendocrine carcinomas.

Download Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2970

Afinitor was introduced by Novartis AG in 2009 for the treatment of advanced renal cell carcinoma. This drug is useful when sunitinib or sorafenib fail to treat the renal cell carcinoma. Sutent is a brand developed by Pfizer Ltd. and is used to treat advanced renal cell carcinoma and gastrointestinal stromal tumor. F. Hoffmann-La Roche Ltd., BioSynthema, Inc., Genentech Inc. and Callisto Pharmaceuticals Pvt. Ltd. are some major companies that are striving to develop drugs for treating various neuroendocrine carcinomas. Avastin, Atiprimod and Lutathera are among other molecules that are currently being studied for their therapeutic efficacy in the treatment of neuroendocrine carcinomas.

Geographically, the market for neuroendocrine carcinoma has been segmented into North America, Europe, Asia Pacific and Rest of the World (RoW). United States and Canada are the two major markets in North America region. North America represented the largest market for neuroendocrine carcinoma in 2013, with a largest market share in terms of revenue (USD Million). According to sources from Cancer.Net, nearly 8,000 people are diagnosed with neuroendocrine tumors every year in the United States.

Many of the key players operating in this market space are based out of U.S and thus consider North America as their primary market for product launch and investment. Also, the well established healthcare infrastructure and reimbursement scenario are among the major factors responsible for North America’s leading position in neuroendocrine carcinoma market. Europe accounted for the second largest market in 2013, followed by Asia Pacific and Rest of the World (RoW). Growing incidence of neuroendocrine carcinoma in Asia Pacific along with the improving economic scenario is likely to play a key role in driving the market growth in the region.

Pre-Book Full Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=2970<ype=S

F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Ltd., Eli Lilly & Company, Amgen, Inc., Ispen SA, Callisto Pharmaceuticals Pvt. Ltd., Bristol-Myers Squibb, Teva Pharmaceuticals, Ltd. and Biosynthema, Inc. are among others operating in the Neuroendocrine carcinoma market.

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Neuroendocrine Carcinoma Market Analysis & Key Trends 2020 here

News-ID: 906712 • Views:

More Releases from Transparency Market Research

Jasmine Extract Market Set to Soar: Projected to Reach US$ 196.2 Mn by 2032
Jasmine Extract Market Set to Soar: Projected to Reach US$ 196.2 Mn by 2032
The global jasmine extract market (재스민 추출물 시장), valued at US$ 77.4 Mn in 2022, is on a promising growth trajectory, projected to expand at a compound annual growth rate (CAGR) of 9.8% from 2022 to 2032. By the end of the forecast period, the market is anticipated to reach an impressive valuation of US$ 196.2 Mn. Get Sample PDF Research Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=84785 Market Overview: Rising Demand and Key Segments The demand for
Brugada Syndrome Market on Track to Surpass USD 2.8 Bn by 2034 at a moderate CAGR of 7.8% | Analysis by Transparency Market Research, Inc.
Brugada Syndrome Market on Track to Surpass USD 2.8 Bn by 2034 at a moderate CAG …
Brugada Syndrome, a rare but potentially life-threatening cardiac condition, has gained increased attention in the medical community due to its implications for sudden cardiac death. This blog post explores the global Brugada Syndrome market, focusing on its segmentation by diagnosis method, treatment type, market dynamics, regional trends, competitive landscape, and future growth projections. In 2023, the global Brugada Syndrome Market (브루가다 증후군 시장) was valued at US$ 1.2 billion. Over the
Cardiac Mapping Market Expected to Achieve 5.8% CAGR, Reaching USD 5.5 Bn by 2034| Exclusive Report by Transparency Market Research, Inc.
Cardiac Mapping Market Expected to Achieve 5.8% CAGR, Reaching USD 5.5 Bn by 203 …
The Cardiac Mapping Market (심장 매핑 시장) is poised at the forefront of revolutionizing electrophysiological techniques, offering critical insights into the diagnosis and treatment of cardiac arrhythmias. This blog post provides a detailed analysis of the global cardiac mapping market, highlighting its segmentation by product type, disease indication, market dynamics, regional trends, competitive landscape, and future growth projections. In 2023, the global cardiac mapping market reached a valuation of US$ 3.0
Platelet-derived Growth Factors (PDGFs) Market is expected to Grow at an 7.0% CAGR and Reach USD 478.0 Mn by 2034| Report by Transparency Market Research, Inc.
Platelet-derived Growth Factors (PDGFs) Market is expected to Grow at an 7.0% CA …
Platelet-derived Growth Factors (PDGFs) play a pivotal role in the field of regenerative medicine, contributing significantly to tissue repair and wound healing. This blog post provides a detailed analysis of the global PDGFs market, encompassing its segmentation by type, application areas, market dynamics, regional insights, competitive landscape, and future growth prospects. In 2023, the global Platelet-derived Growth Factors (PDGFs) Market (혈소판 유래 성장 인자(PDGFs) 시장) was valued at approximately US$ 228.7

All 5 Releases


More Releases for Neuroendocrine

Neuroendocrine Tumor Treatment Market – Forecast to 2026
According to a new market research report published by Global Market Estimates, the Global Neuroendocrine Tumor Treatment Market is projected to grow from USD 1.8 billion in 2021 to USD 2.1 billion by 2026 at a CAGR value of 5.7% between 2021 to 2026. High prevalence of neuropsychiatric malignancy, awareness regarding early cancer diagnosis, and an increasing number of government initiatives, the neuroendocrine tumor therapy market is expected to rise
Neuroendocrine Carcinoma Market Size - Forecasts to 2026
The findings reviewed by GME stated that the Global Neuroendocrine Carcinoma Market will expand with a CAGR value of 10.6 percent from 2021 to 2026. Owing to a rise in the prevalence of neuroendocrine tumors (NETs) across the globe, the global neuroendocrine carcinoma market will grow rapidly during 2021-2026 forecast period. Browse the Report @ https://www.globalmarketestimates.com/market-report/global-neuroendocrine-carcinoma-market-3109 By Site (Gastrointestinal, Lung, Brain, Pancreas, and Others), By Therapy (Surgery, Radiation Therapy, and Chemotherapy), By
Neuroendocrine Cancer Market: Rising Prevalence of Neuroendocrine Cancer and Gro …
The market report titled ‘Global Neuroendocrine Cancer Market - Size, Share and Forecast (2019 - 2026)’ produced by DataM Intelligence analyses the industry dynamics in this competitive space to provide a comprehensive analysis of the market opportunities. Neuroendocrine Cancer Market Segmentation Analysis Total Neuroendocrine Cancer Studies: 2499 By Drug Type Everolimus Sunitinib Malate Lanreotide Octreotide Others Sunitinib (Sutent) and Everolimus (Afinitor) are two major targeted drugs that are being used for the treatment of
Neuroendocrine Tumors Pipeline Review H1 2017
Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Neuroendocrine Tumors - Pipeline Review, H1 2017, provides an overview of the Neuroendocrine Tumors (Oncology) pipeline landscape. Neuroendocrine tumor begins in the hormone-producing cells of the body's neuroendocrine system, which is made up of cells that are a cross between traditional endocrine cells (or hormone-producing cells) and nerve cells. Symptom includes hyperglycemia, diarrhea, loss of appetite/weight loss, thickening or lump in any part
Neuroendocrine Tumors Pipeline Review H1 2017
Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Neuroendocrine Tumors - Pipeline Review, H1 2017, provides an overview of the Neuroendocrine Tumors (Oncology) pipeline landscape. Neuroendocrine tumor begins in the hormone-producing cells of the body's neuroendocrine system, which is made up of cells that are a cross between traditional endocrine cells (or hormone-producing cells) and nerve cells. Symptom includes hyperglycemia, diarrhea, loss of appetite/weight loss, thickening or lump in any part
Global Neuroendocrine Tumor Treatment Market
The Global Neuroendocrine Tumor Treatment Market was valued at US$ 1,197.3 million in 2016 and is projected to expand at a CAGR of 10.5% during the forecast period (2017–2025), as highlighted in a new report published by Coherent Market Insights. Better diagnostic techniques and products in pipeline are expected to be major factors driving growth of the global neuroendocrine tumor treatment market over the foreseeable future. Neuroendocrine Tumor (NET) are diagnosed